Kidney Week

Abstract: TH-PO1046

Clinical Characteristics, Comorbidities, and Management of Patients with CKD: Insights from iCaReMe Global Registry

Session Information

• CKD Progression and Complications: Diagnosis, Prognosis, Risk Factors
  November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

• Pollock, Carol A., Kolling Institute of Medical Research, St Leonards, New South Wales, Australia

Carol A. Pollock,

• Khunti, Kamlesh, University of Leicester, Leicester, United Kingdom

Kamlesh Khunti,

• Heerspink, Hiddo Jan L., Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen, Groningen, Netherlands

Hiddo Jan L. Heerspink,

• Nicolucci, Antonio, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy

Antonio Nicolucci,

• Joshi, Shashank R., Lilavati Hospital & Research Centre), Mumbai, India

Shashank R. Joshi,

• Fenici, Peter, AstraZeneca Italy, Milan, Italy

Peter Fenici,

• Goncalves, Susana, AstraZeneca Argentina, Buenos Aires, Argentina

Susana Goncalves,

• Nguyen Cong, Luong, AstraZeneca Vietnam, Ho Chi Minh City, Viet Nam

Luong Nguyen Cong,

• Vasnawala, Hardik, AstraZeneca India, Bangalore, India

Hardik Vasnawala,

• Hadaoui, Ahmed, AstraZeneca Algeria, Algiers, Algeria

Ahmed Hadaoui,

Background

CKD is recognized as a global health concern with an increased prevalence, and attributable morbidity and mortality particularly in low- and middle-income countries where there is a need to better understand clinical characteristics, and risk factors for CKD within the Cardiovascular Renal Metabolic Continuum. iCaReMe registry is an opportunity to fill this knowledge gap by providing a comprehensive global real-world data source on patients’ characteristics, disease management and outcomes. The objective of our analysis is to describe clinical features, major risk factors, and management of CKD patients based on data from the iCaReMe Registry.

Methods

iCaReMe Global Registry (NCT03549754) is a multinational, prospective, observational study to assess the management and quality of care of patients with CKD, T2D, HTN, and/or HF. We present baseline cross-sectional descriptive analysis of the CKD cohort enrolled from February 2018 to December 2022.

Results

Overall, 2977 adults with CKD (mean age 60.6 years, 54.6% male) were enrolled in 21 countries^* across the six WHO regions^**. DKD and HKD were the most common etiologies. HTN, T2D, dyslipidemia, HF were present in 80.2%, 72.1%, 44.1% and 35.3% of patients respectively. Mean UACR was 556.7 mg/g available in 891 (30%) patients and mean eGFR was 46.1ml/min/1.73m² reported in 2492 (83.7%) patients. ACEi or ARB were prescribed to 37.8% of patients, and 20.6% received an SGLT2i.

Conclusion

Our results highlight opportunities to improve CKD management particularly in patients with CVD multimorbidity and advanced CKD by enhancing the use of albuminuria monitoring and the adoption of evidence-based treatments.

Funding

• Commercial Support – AstraZeneca